Implanon

Selected form

Etonogestrel

Method of action: Contraceptive, Sex Hormones And Modulators Of The Genital System

Treatment option: Pregnancy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Implanon

Implanon is a core entity in reproductive medicine, recognized as a Long-Acting Reversible Contraceptive (LARC) system designed for highly reliable, extended pregnancy prevention. It functions as a single-product hormonal therapy without the inclusion of estrogen.

Property	Description
Active ingredient	Etonogestrel (a synthetic progestogen)
Form	Subdermal implant (rod)
Pharmacological class	Progestogen-only contraceptive
Common use	Contraception / Prevention of pregnancy
Origin	Synthetic (derived from 19-nortestosterone)

What is the Active Ingredient and Class of Implanon?

The medication contains Etonogestrel as its sole active ingredient, a synthetic progestogen derived from desogestrel, making it a monotherapy product. The Etonogestrel is contained within a continuous-release matrix of ethylene vinyl acetate (EVA) copolymer that ensures a steady hormone delivery. This system is a progestin-only contraceptive and explicitly does not contain estrogen. This feature is clinically recognized as beneficial for individuals who have medical restrictions or sensitivities related to the use of combination (estrogen-containing) hormonal methods.

Implanon's Unique Form: A Subdermal Implant

The physical form of the drug is a small, flexible subdermal implant or rod, measuring approximately four centimeters in length and two millimeters in diameter. This form is central to its classification as a LARC. The physical structure is designed for subdermal insertion into the inner upper arm, which is the route of administration intrinsic to its long-term action. The implant provides sustained contraceptive effect, maintaining its highly effective function over a period of years. This long-acting feature differentiates it significantly from daily contraceptive pills, providing highly dependable protection in scenarios such as long-term family planning where consistent compliance is a priority.

The General Purpose of Etonogestrel Monotherapy

The primary purpose of Implanon is pregnancy prevention, achieved through the continuous delivery of Etonogestrel. The active ingredient acts by suppressing ovulation and altering the consistency of the cervical mucus to create a physical barrier. This combined mechanism results in a highly reliable, reversible contraceptive method with a consistent hormonal profile.

Regulatory References

National Institutes of Health (NIH)

What side effects are possible with Implanon?

Possible Side Effects and Safety Information

The safety profile for the etonogestrel implant, as documented by regulatory bodies, organizes adverse events by frequency and affected body system. The most frequently documented adverse events relate to changes in menstrual bleeding patterns (classified as Very Common or Most Common, ge1/10), which can include irregular, prolonged, infrequent, or absent bleeding, often observed during the first year of use.

Other Common (ge1/100 to <1/10) reported side effects grouped under various System-Organ-Classes include headache, weight increase, acne, breast pain, vaginitis, and mood changes like depressed mood.

Serious Adverse Reactions are rare but are documented in official labeling. These include thromboembolic events (such as deep vein thrombosis or pulmonary embolism), which necessitate removal of the implant. The possibility of ectopic pregnancy must be considered if pregnancy occurs. Rare reports also exist of the implant migrating from the insertion site, including into the vasculature.

Safety Restrictions and Population Considerations are explicitly noted. The implant is contraindicated in women with a known history of thrombosis, active liver disease, or known/suspected breast cancer. Specific considerations apply to overweight women, where effectiveness may be decreased during the third year, and for diabetic women, who require careful monitoring due to potential effects on glucose tolerance.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory guidance for the etonogestrel implant, designated for long-acting contraception, defines the overdose scenario based strictly on the device's physical status rather than on a symptom profile.

Overdosage is officially documented to occur if more than one implant is inserted. This circumstance of overexposure is the sole factor defined in regulatory prescribing information as constituting an overdose event.

Official Regulatory Action

Category	Statement Based on Regulatory Guidance
Documented Manifestations	No specific clinical manifestations, signs, or symptoms resulting from overdose are explicitly documented in the official Overdosage section.
Causal Factor	The risk of overdose is defined by the insertion of more than one implant (etonogestrel).
Mandated Emergency Action	In case of suspected overdose, the required emergency action is that the implant should be removed.
Antidote Availability	No specific antidote is documented as known or available for etonogestrel overdose.

When to Seek Urgent Medical Help

Urgent medical attention is required to initiate the mandated procedural action—the removal of the implant—whenever overdosage is suspected due to the insertion of multiple devices. Regulatory documents specify that the removal of the implant is the required management step for this specific overdose context, emphasizing prompt action to resolve the state of overexposure.

Therapeutic Uses of Implanon

The therapeutic role of Implanon is focused on supportive reproductive planning, with relevant use in addressing cyclical symptoms.

Highly Reliable, Multi-Year Pregnancy Prevention

Implanon is a reliable form of long-acting contraception used primarily for pregnancy prevention, addressing the need for sustained reproductive control. This approach contributes to reducing the risk of user error associated with methods requiring daily action. This method may assist in preventing pregnancy for up to three years. This approach is considered relevant when a long-term contraceptive method is appropriate.

Symptom Support and Estrogen-Restricted Contexts

The treatment is relevant for easing certain distressing symptoms. The implant is relevant in contexts where symptomatic support is needed to help manage discomfort associated with menstrual cramps (dysmenorrhea) and to assist in easing the impact of heavier menstrual bleeding (menorrhagia). Furthermore, the progestin-only formulation is applied when appropriate in contexts where functional stability becomes affected by estrogen use, ensuring this method is accessible for supportive reproductive planning.

Quick Fact: Symptom Support for Menstrual Symptoms The progestogen hormone may assist in the supportive management of symptoms related to dysmenorrhea and menorrhagia, contributing to improved day-to-day comfort.

Regulatory References

NHS guidance on the Contraceptive Implant

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Implanon (Etonogestrel Implant)

This section outlines the population eligibility and non-eligibility for Implanon, strictly based on official government regulatory documents.

Contraindicated Populations (Must Not Use)

Use of Implanon is strictly contraindicated for women with the following conditions:

Known or suspected pregnancy (must be ruled out before insertion).
Current or past history of thrombosis or thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism).
Active severe liver disease, hepatic tumors (benign or malignant).
Known or suspected carcinoma of the breast or other progestin-sensitive cancer.
Undiagnosed abnormal genital bleeding.
Hypersensitivity (allergic reaction) to etonogestrel or any component of the implant.

Conditional or Restricted Use

Certain groups require special monitoring or conditional use:

Overweight women: The effectiveness may be reduced over time, and earlier implant replacement may be considered.
Diabetes or hypertension: These conditions require careful observation while using the implant.
Breastfeeding women: Insertion is permitted, but should be delayed until after the fourth postpartum week.

Age and Physiological Status

Implanon is indicated for women of reproductive age. Use in patients with renal insufficiency is not established, as no formal studies were conducted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for the etonogestrel implant is dominated by pharmacokinetic interactions that affect the plasma concentration of the active ingredient. Etonogestrel is primarily metabolized via the cytochrome P450 (CYP) 3A4 enzyme system.

Documented Interaction Patterns

Interaction Type	Agents/Classes	Official Outcome Statement
CYP3A4 Enzyme Induction	Anticonvulsants (e.g., Phenytoin, Carbamazepine), Anti-infectives (e.g., Rifampin), and St. John's wort	Decreased etonogestrel plasma concentrations, leading to a documented risk of reduced contraceptive effectiveness (failure).
CYP3A4 Enzyme Inhibition	Azole antifungals (e.g., Ketoconazole), Macrolide antibiotics (e.g., Clarithromycin)	Increased etonogestrel plasma concentrations due to decreased clearance.

Regulatory Constraints and Considerations

Co-administration with enzyme-inducing medicines or herbal products requires the use of an additional, non-hormonal contraceptive method during the interaction period and for 28 days after stopping the interacting agent. No mandatory timing separation rules (e.g., 'administer X hours apart') are listed for the implant. The official labeling also notes that the risk of reduced effectiveness is particularly relevant in overweight women when co-administered with enzyme-inducing agents.

Mechanism of Action

Suppressing Signals from the Neuroendocrine Axis

The primary mechanism involves etonogestrel activating progesterone receptors in the brain's hypothalamus and pituitary gland. This activity modulates the release of hormones, particularly the Luteinizing Hormone (LH), which is essential for egg release. This focused modulation of the Hypothalamic-Pituitary-Ovarian (HPO) axis prevents the cyclical signal cascade, resulting in the physiological effect of inhibited ovulation.

Altering Local Reproductive Tract Environment

Etonogestrel also exerts a secondary action by modulating receptors within the cervix and uterus. This causes the cervical mucus to exhibit increased viscosity, which reduces sperm motility and migration, while also leading to an atrophic (thin) endometrial lining that exhibits an altered cellular state, rendering it less favorable to blastocyst adhesion. These combined physiological adjustments of the local environment alter the biophysical conditions of the reproductive tract.

Dosage and Administration Information

The use of Implanon is defined by a single, professional subdermal insertion procedure and a non-interruptible three-year course duration.

Administration Feature	Official Use Guideline
Route & Professional Care	The implant is administered via subdermal insertion into the inner side of the non-dominant upper arm. Both placement and removal must be performed only by a trained healthcare professional.
Dosing & Release	A single implant containing 68 mg of etonogestrel is inserted. It provides a continuous release of the hormone, beginning at approximately 60 to 70 mug per day and decreasing over the course of use.
Timing & Duration	The maximum authorized course duration is three years, requiring mandatory removal and replacement for continuation. The timing of initial insertion is critical; if non-standard, a barrier method is required for the first seven days post-insertion.

Procedural Constraints and Adjustments

Before the procedure, the absence of pregnancy must be confirmed. Specific population considerations are recognized. For instance, healthcare providers may consider earlier replacement of the implant for certain individuals, notably overweight women, to ensure the full maintenance of effectiveness across the entire three-year duration. This structured protocol ensures the standardized and high-level use of the device.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Implanon

Evidence for Use in Preventing Pregnancy

Research examining the etonogestrel implant involved large-scale regulatory studies designed around contraceptive study designs, including integrated analyses of pivotal non-controlled trials and randomized controlled trials (RCTs). These studies were designed to evaluate the cumulative probability of pregnancy over the full three-year period. The research was conducted primarily on healthy women of reproductive age, with findings describing the pregnancy rates measured in the study populations.

Research also monitored the hormone levels over time, with data showing patterns related to the maintenance of the necessary concentration for hormone activity thresholds. Furthermore, studies monitored the time to the return of measured fertility following the implant’s removal.

Evidence for Supportive Menstrual Symptom Management

Research exploring the implant for the supportive management of menstrual pain (dysmenorrhea) and heavy bleeding (menorrhagia) mainly involved observational and prospective studies. These studies were applied in research contexts involving fluctuating or unstable symptoms and monitored changes measured during the study period in reported menstrual characteristics and the severity of self-reported pain.

Findings describe patterns observed in the studies related to changes in menstrual bleeding, including subjects documenting the absence of bleeding (amenorrhea) or, alternatively, reporting frequent or prolonged bleeding.

What is Still Uncertain in the Research

Scientific reviews indicate several areas where research is ongoing. One key uncertainty is the lack of large, dedicated, placebo-controlled randomized trials specifically exploring the implant's effects on menstrual symptoms, which limits the certainty of findings in this area.

Comparative evidence is lacking for many direct comparisons between the etonogestrel implant and other hormonal or non-hormonal contraceptive methods. Additionally, data for certain subgroups, such as those with the highest Body Mass Index (BMI), remain insufficient compared to the general population studied.

Key Studies & References

Clinical Profile of Implanon: A Single-Rod Etonogestrel Contraceptive Implant

Frequently Asked Questions (FAQ)

Common questions about Implanon (FAQ)

Q: How quickly does Implanon begin to prevent pregnancy?

A: According to official product information, the implant’s effectiveness can be immediate if it is inserted during the first 5 days of the menstrual period. If the insertion occurs at any other time, a non-hormonal barrier method of contraception must be used for the first 7 days following the procedure to align with official requirements for initiating protection.

Q: Is Implanon the same thing as Nexplanon?

A: Implanon and Nexplanon contain the same active hormone, etonogestrel. Nexplanon is described as the later version. A key difference is that Nexplanon was designed to be radiopaque, meaning it is visible on an X-ray or CT scan, and it includes an improved applicator for insertion.

Q: How does Implanon differ from other types of birth control implants?

A: Official classification defines Implanon as a progestogen-only hormonal system. This means it functions by delivering the hormone etonogestrel without the inclusion of estrogen. This is a primary difference from many other methods, particularly combined hormonal contraceptives.

Q: What happens to my fertility after Implanon is removed?

A: Studies and official information indicate that fertility is described as returning quickly following the removal of the implant. Research studies indicate that ovulation typically returns within six weeks after the implant is taken out.

Q: How long does it take to get pregnant after Implanon removal?

A: Since fertility returns quickly upon removal, it is possible to become pregnant as early as the first week after the implant is taken out. If continuation of pregnancy prevention is desired, a new method is typically initiated immediately upon removal, as the implant's effect ends once it is taken out.

Q: What should I ask my healthcare provider before getting Implanon?

A: Official labeling outlines key conditions that require discussion with a healthcare provider. These include a history of blood clots (thrombosis), liver disease, certain cancers, diabetes, and high blood pressure. This discussion helps confirm eligibility based on documented constraints.

Q: Is Implanon reversible?

A: Yes, Implanon is classified as a Long-Acting Reversible Contraceptive (LARC). The implant can be removed by a trained healthcare professional at any time if the user chooses to discontinue its use before the authorized 3-year course is complete.

Q: What are the ingredients in Implanon besides the active hormone?

A: The medication contains etonogestrel as the active ingredient. The implant rod itself is primarily made of an ethylene vinyl acetate (EVA) copolymer matrix, which is designed for continuous hormone release. The later version (Nexplanon) also contains a small amount of barium sulfate to allow the implant to be located via X-ray.

Q: Is it normal to have bruising at the insertion site?

A: Official product information notes that pain, irritation, swelling, or bruising at the insertion site are all documented as possible problems related to the insertion and removal procedure. These effects commonly resolve over time following the procedure.

Q: What are the reported side effects related to the implant site?

A: Side effects at the insertion site can include pain, swelling, irritation, and bruising. Serious adverse events are documented, which include the potential for scarring, infection, or the implant migrating from the location.

Q: What happens when Implanon expires?

A: The implant is authorized for a course of 3 years. If it is not removed on time, the effects of the active ingredient may continue for a period, but its effectiveness in preventing pregnancy may be reduced past the authorized duration as hormone levels decline. It must be removed after 3 years.

Q: Can Implanon be removed early if needed?

A: The implant can be removed by a healthcare provider at any time if the user chooses to discontinue its use before the 3-year course is complete. Removal is performed via a minor surgical procedure.

Q: Can Implanon interact with common pain relievers?

A: Regulatory documents listing drug interactions focus on agents that affect the metabolism of etonogestrel. Common over-the-counter pain relievers such as ibuprofen, acetaminophen, and aspirin are not listed as agents that affect how the implant works.

Q: What should I do if I can't feel the Implanon rod under my skin?

A: The official label documents that if the implant cannot be felt, reaching out to a healthcare provider is necessary. A non-hormonal barrier method must be used until the implant’s presence and location are confirmed through examination or imaging.

Q: Does Implanon affect bone density over time?

A: The effect of the etonogestrel implant on Bone Mineral Density (BMD) has been monitored in studies. Some evidence indicates small decreases in BMD at certain bone sites after extended use. Official labeling addresses the safety profile but does not list a specific warning about bone density loss.

Q: Can I have an MRI or X-ray with Implanon inserted?

A: The later implant version, Nexplanon, contains barium sulfate which makes it radiopaque, meaning it is visible on X-ray and computed tomography (CT) scans. This feature helps healthcare providers locate the implant if it cannot be felt.

Q: How is the removal process of Implanon different from insertion?

A: Both insertion and removal are minor surgical procedures performed by a trained provider. Removal typically involves a small incision made at the end of the implant and the use of a tool to extract it, which may sometimes require slightly more time than the insertion.

Q: Can Implanon be used while taking anti-seizure medication?

A: Anti-seizure medications such as phenytoin or carbamazepine are documented to potentially decrease the concentration of the hormone. Regulatory documents state that a non-hormonal barrier method is required during co-administration and for 28 days after stopping the interacting agent.

Q: What is the experience like for most users during the first few months of having Implanon?

A: The most common reported experience is a change in the menstrual bleeding pattern. This change, which can include irregular, prolonged, infrequent, or absent bleeding, is often observed during the first 6–12 months as the body adjusts to the active ingredient.

Q: Is there a chance Implanon could be expelled from the body?

A: Official labeling documents that the implant may come out by itself (expulsion). This is documented as potentially related to the insertion technique or the management of the insertion site.

Q: Do studies indicate any long-term effects of using Implanon for multiple years?

A: The implant is authorized for a course of 3 years. The official label lists potential rare, serious complications associated with hormonal contraceptives, such as thrombotic events, that require monitoring and may necessitate removal.

Q: Is a follow-up appointment necessary after Implanon is inserted?

A: Follow-up is advised in official guidelines to allow the provider to confirm the implant is in place by palpation in the arm. Some healthcare providers may recommend a return visit shortly after the insertion procedure.

Q: Does Implanon offer any protection against sexually transmitted infections?

A: No. Official labeling for contraceptive implants explicitly states that they do not protect against sexually transmitted infections (STIs), including HIV/AIDS. Non-hormonal methods, such as barrier methods, are used to help protect against STIs.

Q: What are the typical non-contraceptive benefits sometimes associated with Implanon?

A: Research has monitored the use of the implant for the supportive management of menstrual pain (dysmenorrhea) and reduction of heavy bleeding (menorrhagia). Studies have documented observed patterns related to these changes in menstrual characteristics.

Q: How do I know if Implanon is placed correctly?

A: Correct placement is confirmed immediately after insertion by a healthcare provider through palpation (feeling the implant) in the arm. The patient is also typically asked to feel the rod to confirm it is just under the skin. If it cannot be felt, a healthcare provider may need to use imaging tools like X-ray or ultrasound for confirmation.

How should Implanon be stored and disposed of?

Storage and Disposal Requirements for Implanon (Etonogestrel Implant)

The official labeling defines strict requirements for storing and disposing of the Implanon/NEXPLANON implant and its preloaded applicator.

Storage Constraints

The product must be stored at controlled room temperature, specifically 25 C (77 F), with permitted excursions between 15 C and 30 C. Storage above this range is prohibited, and the product must be protected from freezing. To maintain the sterility of the applicator, it must remain in its original outer carton until insertion and must not be used after the expiration date printed on the package. As with all medicines, the product must be kept out of the sight and reach of children.

Disposal Instructions

Disposal must be managed by a healthcare professional. Any unused or expired product must be discarded in accordance with local requirements for medicinal products. The used applicator and the removed implant are classified as medical waste and must be disposed of as sharps and biohazardous waste following specific institutional and national guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.